申请人:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
公开号:US20210002235A1
公开(公告)日:2021-01-07
Disclosed herein a crystal structure of a caspase inhibitor, and more specifically a crystal structure of an (S)-3-((S)-2-(5-(2-chlorophenyl)isoxazole-3-formylamide)proponamide)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)valeric acid, a preparation method therefor, a crystal polymer, a pharmaceutical composition and uses thereof. The compound A of formula (I) disclosed herein exhibits high crystal structure stability, low hygroscopicity, and advantageously shows physical properties, safety and metabolic stability while having relatively high pharmaceutical value.
本文披露了一种caspase抑制剂的晶体结构,更具体地是一种(S)-3-((S)-2-(5-(2-氯苯基)异噁唑-3-甲酰胺)丙酰胺)-4-氧代-5-(2,3,5,6-四氟苯氧基)戊酸的晶体结构,以及其制备方法,晶体聚合物,药物组合物及其用途。本文披露的式(I)的化合物A表现出高晶体结构稳定性,低吸湿性,并且在具有相对较高的药用价值的同时,具有有利的物理性质,安全性和代谢稳定性。